RA 642

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461105

CAS#: 54093-30-0

Description: RA 642 is a PDE-inhibitor.

Chemical Structure

img
RA 642
CAS# 54093-30-0
Instruction

Theoretical Analysis

MedKoo Cat#: 461105
Name: RA 642
CAS#: 54093-30-0
Chemical Formula: C24H44N8O4
Exact Mass: 508.35
Molecular Weight: 508.660
Elemental Analysis: C, 56.67; H, 8.72; N, 22.03; O, 12.58

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: RA 642; RA-642; RA642; RA 642BS; RA-642BS; RA642BS; RXRA 642; RXRA-642; RXRA642;

IUPAC/Chemical Name: 2,2'-((4,8-bis(diethylamino)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis((2-methoxyethyl)azanediyl))bis(ethan-1-ol)

InChi Key: ROFXYKJBKWRUBS-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H44N8O4/c1-7-29(8-2)21-19-20(26-23(27-21)31(11-15-33)13-17-35-5)22(30(9-3)10-4)28-24(25-19)32(12-16-34)14-18-36-6/h33-34H,7-18H2,1-6H3

SMILES Code: CCN(CC)c1c2c(c(N(CC)CC)nc(N(CCOC)CCO)n2)nc(N(CCOC)CCO)n1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 508.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jonkman FA, Thoolen MJ, Wilffert B, de Jonge A, Timmermans PB, Van Zwieten PA. Effect of salbutamol and the PDE-inhibitor RA 642 on the clonidine withdrawal syndrome in rats. J Auton Pharmacol. 1984 Sep;4(3):199-206. PubMed PMID: 6092386.

2: de la Cruz JP, Moreno A, Mérida F, García-Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats. Pharmacol Toxicol. 1994 Nov;75(5):250-4. PubMed PMID: 7870694.

3: De La Cruz JP, Villalobos MA, Carrasco T, Smith-Agreda JM, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia reperfusion. Brain Res. 1992 Dec 4;597(2):250-6. PubMed PMID: 1472997.

4: Hock CE, Lefer DJ, Lefer AM. Anti-shock actions of the pyrimido-pyrimidine derivative, RA-642. Methods Find Exp Clin Pharmacol. 1986 May;8(5):265-9. PubMed PMID: 3724301.

5: Bellido I, de la Cruz JP, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes. Methods Find Exp Clin Pharmacol. 1991 Jul-Aug;13(6):371-5. PubMed PMID: 1881198.

6: De la Cruz JP, Olveira C, Gonzalez-Correa JA, Benítez A, Sánchez de la Cuesta F. Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue. Gen Pharmacol. 1996 Jul;27(5):855-9. PubMed PMID: 8842690.

7: De la Cruz JP, Sintas A, Moreno A, Garcia-Campos J, Sanchez de la Cuesta F. Dipyridamole and RA-642 inhibit the production of superoxide anion and free radical damage to rat lens. Pharmacol Toxicol. 1991 Sep;69(3):201-4. PubMed PMID: 1665562.

8: De La Cruz JP, Moreno A, Mérida F, García Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. Thromb Res. 1996 Feb 1;81(3):327-37. PubMed PMID: 8928090.

9: de la Cruz JP, Moron D, Sanchez de la Cuesta F. Antiplatelet effect of the pyrimido-pyrimidinic derivative RA-642. Thromb Res. 1991 Aug 15;63(4):463-8. PubMed PMID: 1754999.

10: Hergenröder S, Reichl R. Pharmacological effects of RA 642 on cerebrocortical perfusion in acute hemorrhagic shock in rats. Prog Clin Biol Res. 1989;308:1091-5. PubMed PMID: 2780688.

11: Boswell GW, Munoz AC, Aaron DT, Chin CL, Quinn KP. High-performance liquid chromatographic assay for RA 642, a compound with cardiovascular effect, in human and rabbit serum alpha. J Chromatogr. 1989 Jul 21;491(2):513-8. PubMed PMID: 2808637.

12: Yin M, Liao XL, Tan SJ. [Effects of 2,2'-[(4,8-bis(diethylamino)-pyrimido[5,4-d]pyrimidine-2,6-diyl) di-(2-methoxyethyl)imino]diethanol (RA 642) on experimental scald shock]. Zhongguo Yao Li Xue Bao. 1987 Nov;8(6):533-6. Chinese. PubMed PMID: 3451667.

13: de la Cruz JP, Carrasco T, Ortega G, Sanchez de la Cuesta F. Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes. Lipids. 1992 Mar;27(3):192-4. PubMed PMID: 1522764.

14: Aibiki M, Koyama S, Kanai K, Fujita T, Miyakawa K. [A comparison of effects on renal sympathetic nerve responses to RA642 and catecholamines during hemorrhagic shock in anesthetized rabbits]. Masui. 1988 May;37(5):561-9. Japanese. PubMed PMID: 3411779.

15: Koyama S. Characteristic cardiovascular effects of RA642, a pyrimido-pyrimidine derivative, in anesthetized dogs. J Pharmacol Exp Ther. 1985 May;233(2):480-4. PubMed PMID: 3999030.

16: Koyama S, Manning JW, Takeuchi T. Pyrimido-pyrimidine derivative, RA642, a central pressor agent in cat endotoxin shock. Eur J Pharmacol. 1982 Sep 24;83(3-4):191-8. PubMed PMID: 6293839.

17: Aibiki M, Koyama S, Fujita T. Effects of RA642, a new central pressor agent, on renal sympathetic nerve activity and blood pressure during hemorrhagic shock in rabbits. Circ Shock. 1991 Jun;34(2):240-6. PubMed PMID: 1934324.

18: Koyama S. Cardiovascular improvement due to RA642, a pyrimido-pyrimidine derivative, in canine endotoxin shock. Circ Shock. 1984;13(4):341-51. PubMed PMID: 6478548.